Celgene Corporation (NASDAQ: CELG) director Ernest Mario bought 1,000 shares of CELG common stock for $123.72 per share, according to a SEC filing. Mario made a total investment of $123,725.
Continue reading Celgene Corporation Director Buys 1,000 Shares (CELG)
Shares of Celgene Corporation (NASDAQ: CELG), a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases, have edged higher in pre-market trading today after the company’s POMALYST® was approved by the U.S. Food and Drug Administration (FDA).
Continue reading Celgene Shares Gain after FDA Approval for POMALYST® (CELG)